Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Bone Disease, Metabolic Clear all
Completed Phase 1 Interventional

PS-341 in Treating Patients With Advanced Cancer

NCT00006362
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
bortezomib
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
2
States / cities
Rochester, Minnesota • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 2, 2011 · Synced Jul 23, 2026, 10:56 AM EDT
Completed Phase 1 Interventional

Safety and Tolerability of Intravenous LLP2A-Alendronate for Osteopenia Secondary to Glucocorticoids

NCT03197623
View directory record Official record
Conditions
Osteopenia, Osteoporosis, Osteonecrosis
Interventions
LLP2A-ALENDRONATE, Placebo
Drug
Lead sponsor
Nancy E. Lane, MD
Other
Eligibility
20 Years to 85 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
4
States / cities
Cypress, California • Walnut Creek, California • Duncansville, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Jul 23, 2026, 10:56 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Diabetes/ Endocrine Surveillance in SDS

NCT04275479
View directory record Official record
Conditions
Shwachman-Diamond Syndrome
Interventions
Oral Glucose Tolerance Test, Modified Oral Glucose Tolerance Test, Modified Mixed Meal Tolerance Test, Continuous Glucose Monitor, Food Diary, Medical History Questionnaires
Diagnostic Test · Other · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
3 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 18, 2024 · Synced Jul 23, 2026, 10:56 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Calcimimetics in Hypophosphatemic Rickets

NCT00844740
View directory record Official record
Conditions
Familial Hypophosphatemic Rickets
Interventions
Cinacalcet
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
5 Years to 21 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Jul 23, 2026, 10:56 AM EDT
Recruiting Phase 3 Interventional

A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

NCT06056297
View directory record Official record
Conditions
Neutropenia
Interventions
Mavorixafor, Placebo
Drug
Lead sponsor
X4 Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
22
States / cities
Phoenix, Arizona • Irvine, California • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 23, 2026, 10:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Functional Assessment of Ashwagandaha Root Extract During Weight Loss

NCT03112824
View directory record Official record
Conditions
Stress Reaction, Sleep Disturbance, Craving, Obesity
Interventions
Ashwagandha Root Extract Capsule, Placebo Capsule
Dietary Supplement · Other
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2023 · Synced Jul 23, 2026, 10:56 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Prunes Preventing Bone Loss in Perimenopause

NCT07120997
View directory record Official record
Conditions
Perimenopausal Bone Loss
Interventions
Prunes, Calcium supplement, Vitamin D Supplement
Dietary Supplement
Lead sponsor
Penn State University
Other
Eligibility
44 Years to 55 Years · Female only
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Jul 23, 2026, 10:56 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women With Osteoporosis

NCT00542425
View directory record Official record
Conditions
Osteoporosis
Interventions
teriparatide, Placebo, BA058 20 µg, BA058 40 µg, BA058 80 µg
Drug
Lead sponsor
Radius Health, Inc.
Industry
Eligibility
55 Years to 85 Years · Female only
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 29, 2017 · Synced Jul 23, 2026, 10:56 AM EDT
Completed No phase listed Observational

Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT01146210
View directory record Official record
Conditions
Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Minimally Differentiated Myeloid Leukemia (M0), Childhood Acute Monoblastic Leukemia (M5a), Childhood Acute Monocytic Leukemia (M5b), Childhood Acute Myeloblastic Leukemia With Maturation (M2), Childhood Acute Myeloblastic Leukemia Without Maturation (M1), Childhood Acute Myelomonocytic Leukemia (M4), Childhood Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Fanconi Anemia, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Ringed Sideroblasts, Secondary Myelodysplastic Syndromes, Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Monrovia, California
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Jul 23, 2026, 10:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Understanding Effects of Calcium on the Gut-Bone Axis

NCT06383117
View directory record Official record
Conditions
Healthy, Adult, Calcium, Bone Resorption, Endocrine; Obesity
Interventions
Calcium carbonate, Placebo Control
Dietary Supplement
Lead sponsor
University of Georgia
Other
Eligibility
18 Years to 45 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Athens, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Jul 23, 2026, 10:56 AM EDT
Completed Phase 2 Interventional Results available

Forteo Trial on Idiopathic Osteoporosis in Premenopausal Women

NCT01440803
View directory record Official record
Conditions
Adult Idiopathic Generalized Osteoporosis
Interventions
Teriparatide, Saline Placebo
Drug
Lead sponsor
Elizabeth Shane
Other
Eligibility
20 Years to 45 Years · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Omaha, Nebraska • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Jul 23, 2026, 10:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Higher Protein Diet and Exercise for Optimal Weight Loss in Elderly Women

NCT00912210
View directory record Official record
Conditions
Bone and Body Composition, Obesity, Metabolic Syndrome, Physical Function, Quality of Life
Interventions
Whey protein isolate, Maltodextrin powder supplement
Dietary Supplement
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
60 Years to 80 Years · Female only
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 2, 2009 · Synced Jul 23, 2026, 10:56 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Bone Health in Type 1 Diabetes

NCT00651196
View directory record Official record
Conditions
Type 1 Diabetes, Osteoporosis
Interventions
Not listed
Lead sponsor
Creighton University
Other
Eligibility
19 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 17, 2013 · Synced Jul 23, 2026, 10:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of Different Formulations of Risedronate in Healthy Male and Female Subjects

NCT00846196
View directory record Official record
Conditions
Osteoporosis
Interventions
risedronate DR (Phase III clinical supply), risedronate 35 mg DR (Commercial Tablet)
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
18 Years to 65 Years
Enrollment
538 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
6
States / cities
San Diego, California • Fort Myers, Florida • Miramar, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2011 · Synced Jul 23, 2026, 10:56 AM EDT
Completed Phase 3 Interventional

Postmenopausal Evaluation and Risk-reduction With Lasofoxifene (PEARL)

NCT00141323
View directory record Official record
Conditions
Osteoporosis
Interventions
lasofoxifene, placebo
Drug · Other
Lead sponsor
Ligand Pharmaceuticals
Industry
Eligibility
60 Years to 80 Years · Female only
Enrollment
8,556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
48
States / cities
Birmingham, Alabama • La Jolla, California • Palm Desert, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2011 · Synced Jul 23, 2026, 10:56 AM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Effect of Blueberries on Bone Turnover

NCT02630797
View directory record Official record
Conditions
Osteoporosis, Postmenopausal, Bone Loss, Age-related
Interventions
Blueberry Baseline, Blueberry Low, Blueberry Medium, Blueberry High
Dietary Supplement
Lead sponsor
Purdue University
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated May 6, 2018 · Synced Jul 23, 2026, 10:56 AM EDT
Recruiting Phase 2 Interventional

Effect of Acetylcholinesterase Inhibitors on Bone Metabolism

NCT06041789
View directory record Official record
Conditions
Osteoporosis
Interventions
Donepezil, Memantine
Drug
Lead sponsor
Duke University
Other
Eligibility
50 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Jul 23, 2026, 10:56 AM EDT
Recruiting No phase listed Interventional

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

NCT00935090
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
3'-deoxy-3'-[18F]fluorothymidine
Device
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2028
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 7, 2025 · Synced Jul 23, 2026, 10:56 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Relationship Between Osteoporosis and Chronic Oral Anticoagulation Therapy With Warfarin

NCT00665613
View directory record Official record
Conditions
Osteoporosis
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 100 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Staten Island, New York
Source: ClinicalTrials.gov public record
Updated Oct 13, 2015 · Synced Jul 23, 2026, 10:56 AM EDT
Completed Phase 3 Interventional Results available

A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis

NCT00541658
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
risedronate
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
50 Years and older · Female only
Enrollment
923 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
20
States / cities
Birmingham, Alabama • Oakland, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2013 · Synced Jul 23, 2026, 10:56 AM EDT
Enrolling by invitation Phase 2 Interventional Accepts healthy volunteers

Theophylline for Treatment of Pseudohypoparathyroidism

NCT04240821
View directory record Official record
Conditions
Pseudohypoparathyroidism, Pseudohypoparathyroidism Type 1a, Albright Hereditary Osteodystrophy
Interventions
Theophylline ER
Drug
Lead sponsor
Jaclyn Tamaroff
Other
Eligibility
2 Years to 99 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Jul 23, 2026, 10:56 AM EDT
Completed Phase 2 Interventional

Medical Treatment for Diamond Blackfan Anemia

NCT00001749
View directory record Official record
Conditions
Fanconi's Anemia, Hematologic Disease
Interventions
Antithymocyte globulin, Cyclosporine
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 23, 2026, 10:56 AM EDT
Not listed No phase listed Observational

Study to Examine Insulin Resistance During Growth Hormone Treatment for Short Stature Due to Low Birthweight

NCT00120497
View directory record Official record
Conditions
Fetal Growth Retardation
Interventions
somatropin (rDNA)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
8 Years to 12 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 19, 2011 · Synced Jul 23, 2026, 10:56 AM EDT
Withdrawn Phase 4 Interventional

The Effects of Alendronate After Cure of Primary Hyperparathyroidism

NCT00359385
View directory record Official record
Conditions
Hyperparathyroidism
Interventions
Alendronate 70mg weekly
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 15, 2011 · Synced Jul 23, 2026, 10:56 AM EDT